Important Information for Pacira BioSciences, Inc. Securities Holders
On August 5, 2025, a class action lawsuit was filed in the United States District Court for the Southern District of New York against Pacira BioSciences, Inc. (NASDAQ: PCRX) alleging violations of the Securities Exchange Act of 1934. The complaint alleges that the company and certain of its executives made false and misleading statements and failed to disclose material information to investors during the period from August 2, 2023, to August 8, 2024 (the “Class Period”).
Impact on Investors
If you purchased or acquired Pacira securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The lead plaintiff deadline to apply for appointment as the representative of the class is March 14, 2025. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests, please contact Leslie F. Rosen, Esq., of Rosen Law Firm, P.A., at 212-686-1060, or by email at [[email protected]](mailto:[email protected]).
Allegations Against Pacira
The complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose that:
- Pacira’s financial statements for the periods ended December 31, 2022, and June 30, 2023, contained material misstatements and omissions;
- The company’s sales and marketing efforts for its EXPAREL product were not progressing as planned;
- The company’s financial results were negatively impacted by increased competition and pricing pressures;
As a result of these alleged false and misleading statements, Pacira’s stock traded at artificially inflated prices during the Class Period, causing investors harm.
Impact on the World
The securities class action against Pacira BioSciences, Inc. is significant because it highlights the importance of accurate and transparent financial reporting. When companies fail to disclose material information to investors, it can lead to artificially inflated stock prices and financial losses for investors. This can have ripple effects throughout the economy, as investors may be less likely to trust the stock market and may be hesitant to invest in companies with a history of misrepresentations.
Furthermore, securities class actions can serve as a deterrent to companies engaging in fraudulent activities. The threat of litigation and the potential for substantial damages can encourage companies to be more transparent and honest in their reporting practices.
Conclusion
If you purchased Pacira securities during the Class Period, it is important that you do not wait to take potential legal action. The lead plaintiff deadline to apply for appointment as the representative of the class is March 14, 2025. If you believe you may be entitled to compensation, contact Rosen Law Firm, P.A., to discuss your options. The securities class action against Pacira BioSciences, Inc. serves as a reminder of the importance of accurate and transparent financial reporting and the potential consequences of misrepresentations to investors.
As a responsible investor, it is essential to stay informed about the companies in which you invest and to be aware of any potential risks or red flags. By doing so, you can help protect yourself and the broader investment community from the negative impacts of misrepresentations and fraudulent activities.
